Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats

Chinese Medical Journal

Volumn 125, Issue 13, 2012, Pages 2316-2321

  Zhao, Jia sheng ^a   Zhu, Feng shang ^a   Liu, Su ^b   Yang, Chang qing ^a   Chen, Xi mei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Central Hospital of Zhabei District   (China)

Author keywords

Cyclooxygenases 2; Nonalcoholic steatohepatitis; Nuclear factor kappa B; Peroxisome proliferator activated receptor gamma; Pioglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; CATALASE; CHOLESTEROL; CYCLOOXYGENASE 2; GLUCOSE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN E2; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; FATTY LIVER; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; CYCLOOXYGENASE 2; FATTY LIVER; GLUTATHIONE PEROXIDASE; MALE; MALONDIALDEHYDE; NF-KAPPA B; PPAR GAMMA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863796676     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.13.014     Document Type: Article

References (30)

1. Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 18-23.
2. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009; 50: 204-210.
3. Su L, Wang JH, Cong X, Wang LH, Liu F, Xie XW, et al. Intestinal immune barrier integrity in rats with nonalcoholic hepatic steatosis and steatohepatitis. Chin Med J 2012; 125: 306-311.
4. Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009; 26: 893-907.
5. Sun L, Lü SZ. Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J 2011; 124: 867-872.
6. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560-578.
7. Zelber-Sagi S, Ratziu V, Oren R. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 2011; 17: 3377-3389.
8. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009; 30: 999-1009.
9. Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJ. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr 2008; 138: 1872-1879.
10. Zhao CY, Jiang LL, Li L, Deng ZJ, Liang BL, Li JM. Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease. World J Gastroenterol 2004; 10: 1329-1332.
11. Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, et al. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scand J Gastroenterol 2009; 44: 358-365.
12. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46: 424-429.
13. Harrison SA. Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution? Hepatology 2010; 51: 366-369.
14. Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM. The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res 2008; 2008: 790568.
15. Liu S, Wu HJ, Zhang ZQ, Chen Q, Liu B, Wu JP, et al. The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Eur J Pharmacol 2011; 650: 384-389.
16. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241-246.
17. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837-847.
18. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
19. Chen SW, Chen YX, Shi J, Lin Y, Xie WF. The restorative effect of taurine on experimental nonalcoholic steatohepatitis. Dig Dis Sci 2006; 51: 2225-2234.
20. Tsujimoto T, Kawaratani H, Kitazawa T, Yoshiji H, Fujimoto M, Uemura M, et al. Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138. World J Gastroenterol 2009; 15: 5533-5540.
21. Dai CX, Gao Q, Qiu SJ, Ju MJ, Cai MY, Xu YF, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009; 9: 418.
22. Christensen KV, Leffers H, Watson WP, Sánchez C, Kallunki P, Egebjerg J. Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. BMC Neurosci 2010; 11: 9.
23. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008; 115: 141-150.
24. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 503-522.
25. Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci 2010; 55: 931-940.
26. Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B 2006; 7: 627-633.
27. Yu J, Ip E, Dela Peña A, Hou JY, Sesha J, Pera N, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: role as pro-inflammatory mediator. Hepatology 2006; 43: 826-836.
28. Chêne G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, et al. n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta 2007; 1771: 576-589.
29. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA. Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia 2010; 12: 224-234.
30. Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, et al. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 2009; 275: 247-255.